BRIEF published on 04/08/2026 at 23:59, 18 days 9 hours ago ABIONYX Reports Share Capital and Voting Rights Details Euronext Paris Share Capital Voting Rights Financial Disclosure ABIONYX
PRESS RELEASE published on 04/08/2026 at 23:54, 18 days 9 hours ago Inside Information / Other news releases ABIONYX Pharma releases monthly statement of total voting rights and shares for March 31, 2026, in accordance with French regulations Shares French Regulations Total Voting Rights Biotech Company ABIONYX Pharma
BRIEF published on 03/17/2026 at 19:31, 1 month 9 days ago ABIONYX Pharma makes available the 2025 Universal Registration Document AMF Biopharmaceutical Registration Document ABIONYX Pharma Sepsis
PRESS RELEASE published on 03/17/2026 at 19:26, 1 month 9 days ago Inside Information / Other news releases ABIONYX Pharma announces the availability of its Universal Registration Document for the year 2025, filed with the AMF and accessible on their website AMF Biopharmaceutical Universal Registration Document ABIONYX Pharma Sepsis
BRIEF published on 03/03/2026 at 19:40, 1 month 23 days ago ABIONYX: Information on voting rights and shares as of February 28, 2026 Euronext Paris Share Capital Voting Rights AMF ABIONYX
BRIEF published on 03/03/2026 at 19:40, 1 month 23 days ago ABIONYX Announces February Voting Rights Update Euronext Paris Voting Rights AMF Regulations ABIONYX Pharma February 2026
PRESS RELEASE published on 03/03/2026 at 19:35, 1 month 23 days ago Inside Information / Other news releases ABIONYX Pharma releases monthly statement of total voting rights and shares on Euronext Paris. Company focuses on innovative medicines with lipid science expertise Euronext Paris Shares Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 02/04/2026 at 19:58, 2 months 22 days ago ABIONYX Reports Monthly Voting Rights and Shares Update Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
BRIEF published on 02/04/2026 at 19:58, 2 months 22 days ago Voting rights and shares of ABIONYX on Euronext Paris Euronext Paris Share Capital Voting Rights AMF ABIONYX
PRESS RELEASE published on 02/04/2026 at 19:53, 2 months 22 days ago Inside Information / Other news releases ABIONYX Pharma releases monthly statement on total voting rights and shares. Company focuses on innovative medicines in rare diseases with lipid science expertise Shares Total Voting Rights Monthly Statement ABIONYX Pharma Innovative Medicines
Published on 04/25/2026 at 03:10, 2 days 6 hours ago BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 2 days 11 hours ago Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 2 days 11 hours ago Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 2 days 18 hours ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 2 days 18 hours ago First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Published on 04/27/2026 at 09:05, 41 minutes ago OneLayer Launches Sentry Partner Program to Extend Zero Trust Security for Private Cellular Networks
Published on 04/27/2026 at 09:00, 46 minutes ago Original-Research: THE NAGA GROUP AG (von NuWays AG): BUY
Published on 04/27/2026 at 09:00, 46 minutes ago Original-Research: GFT Technologies SE (von NuWays AG): BUY
Published on 04/27/2026 at 09:00, 46 minutes ago Original-Research: ATOSS Software SE (von NuWays AG): BUY
Published on 04/24/2026 at 17:45, 2 days 16 hours ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 2 days 17 hours ago Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 3 days 14 hours ago Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 3 days 15 hours ago Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group
